ICAP

PURPOSE 4/HPTN 103

A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate the Pharmacokinetics and Safety of Twice Yearly Long-Acting Subcutaneous lenacapavir for Pre-Exposure Prophylaxis in People Who Inject Drugs.

Status

Current

Locations

Our Approach

Research

Health Challenges

HIV/AIDS

Keywords

people who inject drugs